Latest news with #AnalystRatings
Globe and Mail
3 days ago
- Business
- Globe and Mail
Analysts' Opinions Are Mixed on These Technology Stocks: Applied Materials (AMAT) and Xero Limited (OtherXROLF)
Analysts have been eager to weigh in on the Technology sector with new ratings on Applied Materials (AMAT – Research Report) and Xero Limited (XROLF – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Applied Materials (AMAT) Barclays analyst Thomas O'Malley maintained a Hold rating on Applied Materials today and set a price target of $170.00. The company's shares closed last Friday at $185.69. According to O'Malley is a 5-star analyst with an average return of 17.5% and a 59.1% success rate. O'Malley covers the Technology sector, focusing on stocks such as MACOM Technology Solutions Holdings, Credo Technology Group Holding Ltd, and Advanced Micro Devices. ;'> Applied Materials has an analyst consensus of Strong Buy, with a price target consensus of $206.26. Xero Limited (XROLF) In a report released today, Andrew McLeod from Morgan Stanley maintained a Buy rating on Xero Limited, with a price target of A$235.00. The company's shares closed last Friday at $119.99. According to McLeod is a 3-star analyst with an average return of 3.2% and a 55.5% success rate. McLeod covers the NA sector, focusing on stocks such as Telstra Corporation Limited, REA Group Ltd, and News Corp. ;'> Xero Limited has an analyst consensus of Strong Buy, with a price target consensus of $137.95, implying a 16.7% upside from current levels. In a report issued on July 14, Citi also maintained a Buy rating on the stock with a A$210.00 price target.
Globe and Mail
6 days ago
- Business
- Globe and Mail
Analysts Offer Insights on Communication Services Companies: Paramount Global Class B (PARA) and IMAX (IMAX)
Analysts have been eager to weigh in on the Communication Services sector with new ratings on Paramount Global Class B (PARA – Research Report) and IMAX (IMAX – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Paramount Global Class B (PARA) TD Cowen analyst Doug Creutz reiterated a Hold rating on Paramount Global Class B today and set a price target of $14.00. The company's shares closed last Thursday at $13.26. According to Creutz is a 5-star analyst with an average return of 14.8% and a 65.8% success rate. Creutz covers the NA sector, focusing on stocks such as Live Nation Entertainment, Starz Entertainment Corp, and Warner Music Group. ;'> Paramount Global Class B has an analyst consensus of Moderate Sell, with a price target consensus of $12.00, which is a -9.0% downside from current levels. In a report issued on July 22, Needham also maintained a Hold rating on the stock. IMAX (IMAX) In a report released today, Patrick Sholl from Barrington reiterated a Buy rating on IMAX, with a price target of $32.00. The company's shares closed last Thursday at $28.29. According to Sholl is a 2-star analyst with an average return of 0.6% and a 58.8% success rate. Sholl covers the NA sector, focusing on stocks such as Paramount Global Class B, Clear Channel Outdoor, and Nexstar Media Group. ;'> Currently, the analyst consensus on IMAX is a Strong Buy with an average price target of $33.11, which is a 13.7% upside from current levels. In a report issued on July 16, TR | OpenAI – 4o also upgraded the stock to Buy with a $31.00 price target.
Globe and Mail
7 days ago
- Business
- Globe and Mail
Analysts Offer Insights on Technology Companies: Check Point (CHKP) and Palo Alto Networks (PANW)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Check Point (CHKP – Research Report) and Palo Alto Networks (PANW – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Check Point (CHKP) TD Cowen analyst Shaul Eyal reiterated a Buy rating on Check Point today and set a price target of $223.00. The company's shares closed last Thursday at $222.33, close to its 52-week high of $234.36. According to Eyal is a top 25 analyst with an average return of 26.9% and a 70.9% success rate. Eyal covers the Technology sector, focusing on stocks such as CrowdStrike Holdings, Palo Alto Networks, and CyberArk Software. ;'> Currently, the analyst consensus on Check Point is a Moderate Buy with an average price target of $242.42, an 8.8% upside from current levels. In a report issued on July 16, BMO Capital also maintained a Buy rating on the stock with a $250.00 price target. Palo Alto Networks (PANW) TD Cowen analyst Yaron Werber reiterated a Buy rating on Palo Alto Networks today and set a price target of $199.00. The company's shares closed last Thursday at $199.40, close to its 52-week high of $208.39. According to Werber is a 5-star analyst with an average return of 9.9% and a 55.1% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Ionis Pharmaceuticals, and Dianthus Therapeutics. ;'> Currently, the analyst consensus on Palo Alto Networks is a Strong Buy with an average price target of $216.27, which is an 8.7% upside from current levels. In a report issued on July 16, William Blair also maintained a Buy rating on the stock.
Globe and Mail
23-07-2025
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Veeva Systems (VEEV) and Elevance Health (ELV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Veeva Systems (VEEV – Research Report) and Elevance Health (ELV – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Sarepta Therapeutics (SRPT) Sarepta Therapeutics received a Hold rating and a $18.00 price target from Barclays analyst Gena Wang today. The company's shares closed last Monday at $13.32. According to Wang is a 3-star analyst with an average return of 2.8% and a 42.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, 4D Molecular Therapeutics, and BioMarin Pharmaceutical. ;'> The word on The Street in general, suggests a Hold analyst consensus rating for Sarepta Therapeutics with a $30.82 average price target, which is a 140.5% upside from current levels. In a report issued on July 18, Needham also downgraded the stock to Hold with a $50.00 price target. Veeva Systems (VEEV) In a report released today, Saket Kalia from Barclays maintained a Buy rating on Veeva Systems, with a price target of $300.00. The company's shares closed last Monday at $281.00. According to Kalia is a 5-star analyst with an average return of 16.5% and a 64.2% success rate. Kalia covers the Technology sector, focusing on stocks such as CCC Intelligent Solutions Holdings, Procore Technologies, and CrowdStrike Holdings. ;'> The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $295.52 average price target, which is a 4.5% upside from current levels. In a report issued on July 14, Wells Fargo also maintained a Buy rating on the stock with a $300.00 price target. Elevance Health (ELV) Barclays analyst Andrew Mok CFA maintained a Buy rating on Elevance Health today and set a price target of $327.00. The company's shares closed last Monday at $276.45. According to CFA is ranked 0 out of 5 stars with an average return of -8.4% and a 41.1% success rate. CFA covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Alignment Healthcare. ;'> Currently, the analyst consensus on Elevance Health is a Strong Buy with an average price target of $380.47, a 36.7% upside from current levels. In a report issued on July 8, Bernstein also maintained a Buy rating on the stock with a $585.00 price target.
Globe and Mail
17-07-2025
- Business
- Globe and Mail
PNC Financial Reports Strong Q2 2025 Results
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. PNC Financial ( (PNC)) has issued an announcement. On July 16, 2025, PNC Financial Services Group reported strong financial results for the second quarter of 2025, with a net income of $1.6 billion and a 4% revenue growth. The company experienced its strongest loan growth since the fourth quarter of 2022, maintained stable noninterest expenses, and announced a dividend increase, reflecting its continued financial strength. PNC's strategic priorities include expanding its client base and leveraging technology for superior client service, which contributed to record treasury management revenue and increased brokerage assets. The company also reported improved credit quality and maintained its stress capital buffer at the regulatory minimum. The most recent analyst rating on (PNC) stock is a Buy with a $212.00 price target. To see the full list of analyst forecasts on PNC Financial stock, see the PNC Stock Forecast page. Spark's Take on PNC Stock According to Spark, TipRanks' AI Analyst, PNC is a Outperform. PNC Financial's strong financial performance and strategic focus on capital return are the most significant factors driving the score. The technical analysis suggests caution due to overbought signals, while the valuation remains fair with an attractive dividend yield. The earnings call reinforces confidence in PNC's resilience despite potential market challenges. To see Spark's full report on PNC stock, click here. More about PNC Financial PNC Financial Services Group, Inc. operates in the financial services industry, offering a wide range of financial products and services on a national basis. The company focuses on corporate banking, business credit, treasury management, retail banking, and asset management, leveraging technology to enhance client service and ensure safety and soundness. Average Trading Volume: 2,267,611 Technical Sentiment Signal: Strong Buy Current Market Cap: $78.08B For detailed information about PNC stock, go to TipRanks' Stock Analysis page.
